ODAC 30% Off Registration, Use Code: JDD30
Skip to main content

Ethnic Disparities in Folliculitis Following Tapinarof Use: A Retrospective Cohort Study

December 2026 | Volume 25 | Issue 12 | 9627 | Copyright © December 2026


Published online November 16, 2026

Areeba Ahmed MD,a Sahithi Talasila MD,b Hamza Malick MD,c Umer Nadir MD,c,e Dario Kivelevitch MDc-e

aDepartment of Medicine, University of Louisville, Louisville, KY
bTransitional Year Residency, Orange Park Hospital, Orange Park, FL
cDivision of Dermatology, Baylor University Medical Center, Dallas, TX
dClarity Dermatology, Dallas, TX
eTexas A&M College of Medicine, Dallas, TX

Abstract
To the Editor,

Tapinarof, a topical aryl hydrocarbon receptor (AhR) agonist, is approved for psoriasis and atopic dermatitis (AD).1 Folliculitis and contact dermatitis are the most frequently reported dermatologic adverse events.2 Tapinarof-induced folliculitis may stem from AhR-driven abnormal keratinization and follicular plugging.3 We aimed to quantify folliculitis risk following tapinarof use and assess racial/ethnic disparities.

Using the TriNetX Research Network, we conducted two retrospective cohort analyses of adults (≥18) using tapinarof. We queried codes from the 10th revision of the International Classification of Diseases (ICD-10) and RxNorm from September 1, 2022, to September 1, 2025, as tapinarof received FDA approval in May 2022. For the first analysis, tapinarof users were compared with a matched moisturizer cohort; for the second, tapinarof users were compared with a matched topical corticosteroid cohort. We excluded patients with pre-existing folliculitis, other follicular disorders, active skin infection, immunosuppressive conditions/medication use, concurrent exposure to both tapinarof and a control product, or concurrent exposure to both control products. Propensity score matching was performed for age, demographics, comorbidities, and indications (psoriasis/AD) to minimize confounding. Risk ratios (RR) and absolute risk differences (ARD) were assessed, including subgroup analyses by race/ethnicity (P<0.05).